Cardiac myosin inhibitor
- Directly reduces cardiac myosin-actin cross-bridging → ↓ hypercontractility
- Relieves outflow obstruction in hypertrophic cardiomyopathy
- Over-inhibition → systolic dysfunction; ejection fraction monitoring
- Reduces excessive cardiac contractility
- Over-inhibition produces systolic dysfunction
Drugs with this mechanism (2)
- Aficamten — Shorter-acting cardiac myosin inhibitor for obstructive HCM; echo monitoring guards against systolic failure.
- Mavacamten — Cardiac myosin inhibitor for obstructive hypertrophic cardiomyopathy.
All mechanisms · Open Cardiac myosin inhibitor in the interactive console ↗